Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
4.170
-0.070 (-1.65%)
At close: Apr 7, 2026, 4:00 PM EDT
4.110
-0.060 (-1.44%)
Pre-market: Apr 8, 2026, 8:55 AM EDT

Aptevo Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
---3.1112.29
Revenue Growth (YoY)
----74.67%185.26%
Gross Profit
---3.1112.29
Selling, General & Admin
11.7710.2211.7713.8714.7
Research & Development
14.5414.3817.1117.8818.99
Total Operating Expenses
26.3124.628.8831.7633.69
Operating Income
-26.31-24.6-28.88-28.64-21.4
Total Non-Operating Income (Expense)
0.350.4710.2335.66-8.01
Pretax Income
-25.97-24.13-17.418.03-28.46
Net Income
-27.54-24.13-34.8216.05-56.91
Minority Interest in Earnings
1.57----
Earnings From Discontinued Operations
--1.241.010.95
Net Income to Common
-27.54-24.13-34.8216.05-56.91
Shares Outstanding (Basic)
00000
Shares Outstanding (Diluted)
00000
Shares Change (YoY)
41038.85%8709.15%-8.85%38.25%
EPS (Basic)
-87.27-31460.23-870550.00808790.40-3674721.60
EPS (Diluted)
-87.27-31460.23-870550.00802929.60-3674721.60
Shares Outstanding
0.940000
Free Cash Flow
-25.59-23.79-11.73-21.05-22.39
Free Cash Flow Per Share
-81.11-31010.43-1347214.24-2417749.95-2799410.78
Gross Margin
---100.00%100.00%
Operating Margin
----919.75%-174.10%
Profit Margin
---483.01%-470.75%
FCF Margin
----676.01%-182.17%
EBITDA
-26.07-24.25-28.31-27.74-20.26
EBITDA Margin
----890.82%-164.79%
EBIT
-26.31-24.6-28.88-28.64-21.4
EBIT Margin
----919.75%-174.10%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q